Fosamax and Osteonecrosis of the Jaw: Scientific Evidence of Causation

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

Legacy of General Health Information and the Emergence of Drug Safety Concerns

The legacy of general health and science information has long served as a foundation for public understanding of medical conditions and treatments. Within this broad context, discussions of bone health and pharmaceutical interventions have been standard, with a focus on therapeutic benefits and routine side effects. As this informational heritage evolves, it increasingly accommodates nuanced explorations of specific drug-safety profiles, particularly for medications prescribed in mass-production settings. One such area of growing attention involves bisphosphonates, a class of drugs widely used for osteoporosis management. The transition from general health discourse to a more specialized concern emerges when considering the potential for rare but serious adverse events associated with long-term exposure. In occupational and clinical environments where these medications are frequently administered or handled, the risk profile shifts from a population-level perspective to one of individual exposure monitoring. This pivot requires a careful examination of how routine pharmaceutical use, when scaled across large patient populations, may reveal patterns of uncommon complications. The focus here is not on mechanistic pathways but on the epidemiological and clinical recognition of such patterns, particularly as they relate to jaw health. Thus, the bridge from general health information leads to a targeted inquiry into the relationship between Fosamax exposure and the risk of osteonecrosis of the jaw, without delving into disease-specific mechanisms.

Fosamax: Indications, Mechanism, and the Risk of Osteonecrosis of the Jaw

Fosamax (alendronate) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its mechanism involves inhibiting bone resorption, which increases bone mass and reduces fracture incidence. However, a serious adverse effect associated with bisphosphonates, including Fosamax, is osteonecrosis of the jaw (ONJ). Osteonecrosis of the jaw is a condition characterized by exposed, non-healing bone in the maxillofacial region. Clinical presentation typically involves areas of exposed bone that persist for more than eight weeks, often accompanied by pain, swelling, infection, or drainage. Diagnosis is primarily clinical, based on visual examination and patient history, and may be supported by imaging studies to rule out other pathologies. The condition can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Mechanistic Pathways and Animal Model Evidence

The mechanistic pathways linking Fosamax to ONJ are not fully elucidated, but research provides insights into jawbone-specific responses. Multiscale characterization of jawbone in animal models treated with bisphosphonates, including alendronate (the active ingredient in Fosamax), has been conducted to understand bone-related complications. Studies using estrogen-deficient rats treated with alendronate have examined effects on jawbone properties, including static and dynamic mechanical stability of teeth in the alveolar socket, tissue mineral density distribution, and nanoindentation properties of the jawbone matrix (https://pubmed.ncbi.nlm.nih.gov/40345077/). These investigations aim to provide comprehensive information that can help better understand jawbone-specific responses to bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/). The proposed mechanisms include suppression of bone turnover, which impairs the jawbone's ability to repair microdamage and maintain vascularity, leading to avascular necrosis. Additionally, bisphosphonates may have anti-angiogenic effects, reducing blood supply to the jawbone, and may alter immune responses, increasing susceptibility to infection.

Warnings in Prescribing Information and Clinical Risk Management

Regarding the adequacy of warnings, the prescribing information for Fosamax includes a specific section on osteonecrosis of the jaw. The label states that ONJ has been reported in patients taking bisphosphonates, including Fosamax, and notes that it can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The label also identifies known risk factors and advises that the risk of ONJ may increase with duration of exposure to bisphosphonates. For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). These warnings provide healthcare providers and patients with information to assess and mitigate risk, though the adequacy of such warnings in clinical practice may depend on how effectively they are communicated and acted upon.

Causation Considerations: Temporal Relationship and Biological Plausibility

For affected patients, causation-related considerations involve evaluating the temporal relationship between Fosamax exposure and the development of ONJ. The time to onset of symptoms after starting the drug can vary from one day to several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients experience relief of symptoms after stopping the drug, but a subset may have recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56), indicating that while ONJ is a known risk, it is not common in the general osteoporosis population. Causation is further supported by the biological plausibility of bisphosphonate-induced bone turnover suppression and the observed dose-response relationship with duration of exposure. The timeline between exposure and documented harm can vary widely. ONJ may develop after months to years of bisphosphonate use, with risk increasing with longer exposure. The label notes that the risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For patients who develop ONJ, management typically involves discontinuation of the bisphosphonate, conservative debridement, antibiotics, and oral hygiene measures. The label advises discontinuing use if severe symptoms develop (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In summary, scientific evidence supports a causal association between Fosamax and osteonecrosis of the jaw, with mechanistic pathways involving suppressed bone turnover and impaired healing. Warnings in the prescribing information address this risk, but clinical vigilance remains essential. Patients and healthcare providers should weigh the benefits of Fosamax for osteoporosis against the potential for ONJ, particularly in those with additional risk factors.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is osteonecrosis of the jaw (ONJ) and how is it diagnosed?

Osteonecrosis of the jaw is a condition characterized by exposed, non-healing bone in the maxillofacial region. Clinical presentation typically involves areas of exposed bone that persist for more than eight weeks, often accompanied by pain, swelling, infection, or drainage. Diagnosis is primarily clinical, based on visual examination and patient history, and may be supported by imaging studies to rule out other pathologies. The condition can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

What are the known risk factors for developing ONJ while taking Fosamax?

Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates.

Is there scientific evidence supporting a causal link between Fosamax and ONJ?

Yes, scientific evidence supports a causal association between Fosamax and osteonecrosis of the jaw. Mechanistic pathways involve suppression of bone turnover, which impairs the jawbone's ability to repair microdamage and maintain vascularity, leading to avascular necrosis. Animal model studies have examined jawbone-specific responses to alendronate (https://pubmed.ncbi.nlm.nih.gov/40345077/). Additionally, the prescribing information includes warnings about ONJ and notes that the risk may increase with duration of exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.